STAT+: Extended Use of Nektar Therapeutics Drug Shows Promise in Alopecia

Why It Matters

Rezpeg could become a safer, oral alternative for severe alopecia areata, expanding treatment options and capturing a sizable market currently limited by safety concerns of existing drugs.

Key Takeaways

• Rezpeg yields 27% SALT Score 20 after one year.
• Efficacy comparable to low‑dose Olumiant, Lilly’s approved drug.
• No direct head‑to‑head trial conducted yet.
• Phase 3 trial slated for later 2026.
• Oral therapy could expand options for severe alopecia patients.

Pulse Analysis

Alopecia areata affects roughly 2% of the population, with severe cases causing extensive hair loss and significant psychosocial impact. Current pharmacologic options are limited to injectable JAK inhibitors and oral agents like Olumiant, which carry safety warnings related to infections and cardiovascular risk. The market for effective, well‑tolerated treatments is therefore primed for disruption, especially as patients and clinicians seek convenient, long‑term solutions.

In its latest Phase 2 extension study, Nektar reported that 27% of participants achieved a SALT Score 20 after twelve months of rezpeg therapy, a benchmark indicating robust regrowth across most of the scalp. This response rate rivals the outcomes seen with low‑dose Olumiant, suggesting that rezpeg may deliver comparable efficacy with a potentially different safety profile. While the trial did not directly compare the two drugs, the data hint at a competitive edge for rezpeg, particularly if it can avoid the hematologic and hepatic adverse events that have limited Olumiant’s use.

Looking ahead, Nektar’s plan to launch a Phase 3 trial later in 2026 positions the company to capitalize on a market projected to exceed $1 billion globally. A successful Phase 3 readout could attract partnership interest from larger pharmaceutical firms and accelerate regulatory approval pathways. For investors, rezpeg represents a high‑upside asset in the dermatology space, promising both revenue growth and diversification beyond Nektar’s oncology pipeline.